Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Apr;84(7):951–958. doi: 10.1054/bjoc.2000.1679

Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line

P S Mackie 1, J L Fisher 1, H Zhou 2, P F M Choong 1
PMCID: PMC2363848  PMID: 11286476

Abstract

Local growth of osteosarcoma involves destruction of host bone by proteolytic mechanisms and/or host osteoclast activation. Osteoclast formation and activity are regulated by osteoblast-derived factors such as the osteoclast differentiating factor, receptor activator of NF-κB ligand (RANKL) and the inhibitor osteoprotegerin (OPG). We have investigated the in vitro effects of bisphosphonates on a clonal rat osteosarcoma cell line. The aminobisphosphonate pamidronate was added to UMR 106-01 cell cultures (10−8M to 10−4M up to 5 days). The non-aminobisphosphonate clodronate was administered for the same time periods (10−6M to 10−2M). Cell proliferation, apoptosis and mRNA expression was assessed. Both agents inhibited cell proliferation in a time- and dose-dependent manner. ELISA analysis demonstrated an increase in DNA fragmentation although there was no significant dose-related difference between the doses studied. Bisphosphonate-treated cultures had a greater subpopulation of cells exhibiting morphological changes of apoptosis. Expression of mRNA for osteopontin and RANKL was down-regulated by both agents, while the expression of mRNA for alkaline phosphatase, pro-α1(I) collagen and OPG was not altered. Out in vitro work suggests the bisphosphonates not only have direct effects on osteosarcoma cell growth and apoptosis, but also, by altering the relative expression of osteoclast-regulating factors, they may inhibit the activity of osteoclasts and their recruitment. © 2001 Cancer Research Campaignhttp://www.bjcancer.com

Keywords: osteosarcoma, bisphosphonates, apoptosis, osteopontin, RANKL, osteoprotegerin

Full Text

The Full Text of this article is available as a PDF (262.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adami S. Bisphosphonates in prostate carcinoma. Cancer. 1997 Oct 15;80(8 Suppl):1674–1679. doi: 10.1002/(sici)1097-0142(19971015)80:8+<1674::aid-cncr18>3.3.co;2-d. [DOI] [PubMed] [Google Scholar]
  2. Arends M. J., Morris R. G., Wyllie A. H. Apoptosis. The role of the endonuclease. Am J Pathol. 1990 Mar;136(3):593–608. [PMC free article] [PubMed] [Google Scholar]
  3. Behrend E. I., Craig A. M., Wilson S. M., Denhardt D. T., Chambers A. F. Expression of antisense osteopontin RNA in metastatic mouse fibroblasts is associated with reduced malignancy. Ann N Y Acad Sci. 1995 Apr 21;760:299–301. doi: 10.1111/j.1749-6632.1995.tb44640.x. [DOI] [PubMed] [Google Scholar]
  4. Behrend E. I., Craig A. M., Wilson S. M., Denhardt D. T., Chambers A. F. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res. 1994 Feb 1;54(3):832–837. [PubMed] [Google Scholar]
  5. Bloomfield D. J. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol. 1998 Mar;16(3):1218–1225. doi: 10.1200/JCO.1998.16.3.1218. [DOI] [PubMed] [Google Scholar]
  6. Boissier S., Magnetto S., Frappart L., Cuzin B., Ebetino F. H., Delmas P. D., Clezardin P. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 1997 Sep 15;57(18):3890–3894. [PubMed] [Google Scholar]
  7. Brown L. F., Papadopoulos-Sergiou A., Berse B., Manseau E. J., Tognazzi K., Perruzzi C. A., Dvorak H. F., Senger D. R. Osteopontin expression and distribution in human carcinomas. Am J Pathol. 1994 Sep;145(3):610–623. [PMC free article] [PubMed] [Google Scholar]
  8. Carlin B. I., Andriole G. L. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer. 2000 Jun 15;88(12 Suppl):2989–2994. doi: 10.1002/1097-0142(20000615)88:12+<2989::aid-cncr14>3.3.co;2-h. [DOI] [PubMed] [Google Scholar]
  9. Chan Y. L., Gutell R., Noller H. F., Wool I. G. The nucleotide sequence of a rat 18 S ribosomal ribonucleic acid gene and a proposal for the secondary structure of 18 S ribosomal ribonucleic acid. J Biol Chem. 1984 Jan 10;259(1):224–230. [PubMed] [Google Scholar]
  10. Chikatsu N., Takeuchi Y., Tamura Y., Fukumoto S., Yano K., Tsuda E., Ogata E., Fujita T. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun. 2000 Jan 19;267(2):632–637. doi: 10.1006/bbrc.1999.2008. [DOI] [PubMed] [Google Scholar]
  11. Coleman R. E., Purohit O. P. Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev. 1993 Jan;19(1):79–103. doi: 10.1016/0305-7372(93)90028-p. [DOI] [PubMed] [Google Scholar]
  12. Craig A. M., Nemir M., Mukherjee B. B., Chambers A. F., Denhardt D. T. Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/osteopontin: enhanced expression in H-ras-transformed 3T3 cells. Biochem Biophys Res Commun. 1988 Nov 30;157(1):166–173. doi: 10.1016/s0006-291x(88)80028-7. [DOI] [PubMed] [Google Scholar]
  13. Denhardt D. T., Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993 Dec;7(15):1475–1482. [PubMed] [Google Scholar]
  14. Diel I. J., Solomayer E. F., Costa S. D., Gollan C., Goerner R., Wallwiener D., Kaufmann M., Bastert G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998 Aug 6;339(6):357–363. doi: 10.1056/NEJM199808063390601. [DOI] [PubMed] [Google Scholar]
  15. Dodds R. A., Connor J. R., James I. E., Rykaczewski E. L., Appelbaum E., Dul E., Gowen M. Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: an in vitro and ex vivo study of remodeling bone. J Bone Miner Res. 1995 Nov;10(11):1666–1680. doi: 10.1002/jbmr.5650101109. [DOI] [PubMed] [Google Scholar]
  16. Evans C. E., Braidman I. P. Effects of two novel bisphosphonates on bone cells in vitro. Bone Miner. 1994 Aug;26(2):95–107. doi: 10.1016/s0169-6009(08)80055-4. [DOI] [PubMed] [Google Scholar]
  17. Flanagan A. M., Chambers T. J. Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone. Bone Miner. 1989 Apr;6(1):33–43. doi: 10.1016/0169-6009(89)90021-4. [DOI] [PubMed] [Google Scholar]
  18. García-Moreno C., Serrano S., Nacher M., Farré M., Díez A., Mariñoso M. L., Carbonell J., Mellibovsky L., Nogués X., Ballester J. Effect of alendronate on cultured normal human osteoblasts. Bone. 1998 Mar;22(3):233–239. doi: 10.1016/s8756-3282(97)00270-6. [DOI] [PubMed] [Google Scholar]
  19. Gardner H. A., Berse B., Senger D. R. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene. 1994 Aug;9(8):2321–2326. [PubMed] [Google Scholar]
  20. Goziotis A., Sukhu B., Torontali M., Dowhaniuk M., Tenenbaum H. C. Effects of bisphosphonates APD and HEBP on bone metabolism in vitro. Bone. 1995 Apr;16(4 Suppl):317S–327S. doi: 10.1016/8756-3282(95)00044-e. [DOI] [PubMed] [Google Scholar]
  21. Helfrich M. H., Nesbitt S. A., Dorey E. L., Horton M. A. Rat osteoclasts adhere to a wide range of RGD (Arg-Gly-Asp) peptide-containing proteins, including the bone sialoproteins and fibronectin, via a beta 3 integrin. J Bone Miner Res. 1992 Mar;7(3):335–343. doi: 10.1002/jbmr.5650070314. [DOI] [PubMed] [Google Scholar]
  22. Horwood N. J., Elliott J., Martin T. J., Gillespie M. T. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology. 1998 Nov;139(11):4743–4746. doi: 10.1210/endo.139.11.6433. [DOI] [PubMed] [Google Scholar]
  23. Jilka R. L., Weinstein R. S., Bellido T., Parfitt A. M., Manolagas S. C. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res. 1998 May;13(5):793–802. doi: 10.1359/jbmr.1998.13.5.793. [DOI] [PubMed] [Google Scholar]
  24. Kartsogiannis V., Zhou H., Horwood N. J., Thomas R. J., Hards D. K., Quinn J. M., Niforas P., Ng K. W., Martin T. J., Gillespie M. T. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone. 1999 Nov;25(5):525–534. doi: 10.1016/s8756-3282(99)00214-8. [DOI] [PubMed] [Google Scholar]
  25. Luckman S. P., Hughes D. E., Coxon F. P., Graham R., Russell G., Rogers M. J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998 Apr;13(4):581–589. doi: 10.1359/jbmr.1998.13.4.581. [DOI] [PubMed] [Google Scholar]
  26. Majeska R. J., Port M., Einhorn T. A. Attachment to extracellular matrix molecules by cells differing in the expression of osteoblastic traits. J Bone Miner Res. 1993 Mar;8(3):277–289. doi: 10.1002/jbmr.5650080305. [DOI] [PubMed] [Google Scholar]
  27. Martin T. J., Ingleton P. M., Underwood J. C., Michelangeli V. P., Hunt N. H., Melick R. A. Parathyroid hormone-responsive adenylate cyclase in induced transplantable osteogenic rat sarcoma. Nature. 1976 Apr 1;260(5550):436–438. doi: 10.1038/260436a0. [DOI] [PubMed] [Google Scholar]
  28. Merry K., Dodds R., Littlewood A., Gowen M. Expression of osteopontin mRNA by osteoclasts and osteoblasts in modelling adult human bone. J Cell Sci. 1993 Apr;104(Pt 4):1013–1020. doi: 10.1242/jcs.104.4.1013. [DOI] [PubMed] [Google Scholar]
  29. Oldberg A., Franzén A., Heinegård D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A. 1986 Dec;83(23):8819–8823. doi: 10.1073/pnas.83.23.8819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Orr F. W., Sanchez-Sweatman O. H., Kostenuik P., Singh G. Tumor-bone interactions in skeletal metastasis. Clin Orthop Relat Res. 1995 Mar;(312):19–33. [PubMed] [Google Scholar]
  31. Plotkin L. I., Weinstein R. S., Parfitt A. M., Roberson P. K., Manolagas S. C., Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999 Nov;104(10):1363–1374. doi: 10.1172/JCI6800. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Reinholt F. P., Hultenby K., Oldberg A., Heinegård D. Osteopontin--a possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4473–4475. doi: 10.1073/pnas.87.12.4473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ross F. P., Chappel J., Alvarez J. I., Sander D., Butler W. T., Farach-Carson M. C., Mintz K. A., Robey P. G., Teitelbaum S. L., Cheresh D. A. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem. 1993 May 5;268(13):9901–9907. [PubMed] [Google Scholar]
  34. Russell R. G., Rogers M. J., Frith J. C., Luckman S. P., Coxon F. P., Benford H. L., Croucher P. I., Shipman C., Fleisch H. A. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res. 1999 Oct;14 (Suppl 2):53–65. doi: 10.1002/jbmr.5650140212. [DOI] [PubMed] [Google Scholar]
  35. Sahni M., Guenther H. L., Fleisch H., Collin P., Martin T. J. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest. 1993 May;91(5):2004–2011. doi: 10.1172/JCI116422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D. D., Golub E., Rodan G. A. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991 Dec;88(6):2095–2105. doi: 10.1172/JCI115539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Senaratne S. G., Pirianov G., Mansi J. L., Arnett T. R., Colston K. W. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000 Apr;82(8):1459–1468. doi: 10.1054/bjoc.1999.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Shipman C. M., Rogers M. J., Apperley J. F., Russell R. G., Croucher P. I. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 1997 Sep;98(3):665–672. doi: 10.1046/j.1365-2141.1997.2713086.x. [DOI] [PubMed] [Google Scholar]
  39. Simonet W. S., Lacey D. L., Dunstan C. R., Kelley M., Chang M. S., Lüthy R., Nguyen H. Q., Wooden S., Bennett L., Boone T. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997 Apr 18;89(2):309–319. doi: 10.1016/s0092-8674(00)80209-3. [DOI] [PubMed] [Google Scholar]
  40. Sodek J., Chen J., Nagata T., Kasugai S., Todescan R., Jr, Li I. W., Kim R. H. Regulation of osteopontin expression in osteoblasts. Ann N Y Acad Sci. 1995 Apr 21;760:223–241. doi: 10.1111/j.1749-6632.1995.tb44633.x. [DOI] [PubMed] [Google Scholar]
  41. Tan P. L., Katz J. M., Ames R., Caughey D. E., Gray H. D., Ibbertson H. K., Watson J. D. Aminobisphosphonate inhibition of interleukin-1-induced bone resorption in mouse calvariae. Arthritis Rheum. 1988 Jun;31(6):762–768. doi: 10.1002/art.1780310610. [DOI] [PubMed] [Google Scholar]
  42. Thiébaud D., Leyvraz S., von Fliedner V., Perey L., Cornu P., Thiébaud S., Burckhardt P. Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer. 1991;27(1):37–41. doi: 10.1016/0277-5379(91)90056-j. [DOI] [PubMed] [Google Scholar]
  43. Vitté C., Fleisch H., Guenther H. L. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology. 1996 Jun;137(6):2324–2333. doi: 10.1210/endo.137.6.8641182. [DOI] [PubMed] [Google Scholar]
  44. Wong B. R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett F. S., 3rd, Frankel W. N. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem. 1997 Oct 3;272(40):25190–25194. doi: 10.1074/jbc.272.40.25190. [DOI] [PubMed] [Google Scholar]
  45. Yasuda H., Shima N., Nakagawa N., Mochizuki S. I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998 Mar;139(3):1329–1337. doi: 10.1210/endo.139.3.5837. [DOI] [PubMed] [Google Scholar]
  46. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597–3602. doi: 10.1073/pnas.95.7.3597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Yoshida H., Hayashi S., Kunisada T., Ogawa M., Nishikawa S., Okamura H., Sudo T., Shultz L. D., Nishikawa S. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature. 1990 May 31;345(6274):442–444. doi: 10.1038/345442a0. [DOI] [PubMed] [Google Scholar]
  48. Yu X., Schøller J., Foged N. T. Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106. Bone. 1996 Oct;19(4):339–345. doi: 10.1016/s8756-3282(96)00184-6. [DOI] [PubMed] [Google Scholar]
  49. van der Pluijm G., Vloedgraven H., van Beek E., van der Wee-Pals L., Löwik C., Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 1996 Aug 1;98(3):698–705. doi: 10.1172/JCI118841. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES